Physician profile
Saima Ali
NPI 1134410285
$6,514.06
in general payments reported to CMS, 2019-2025
51 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $1,081 · 2023: $1,633 · 2024: $1,789 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,980 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,980.37 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,042.02 | 2021-2025 | Qulipta, Duopa, Botox |
| Sk Life Science, INC. | $489.75 | 2023-2025 | Xcopri |
| Pfizer INC. | $469.27 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $460.16 | 2021-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $290.43 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $251.74 | 2021-2025 | |
| Lilly USA, LLC | $231.04 | 2023-2025 | Emgality, Reyvow, Kisunla |
| Novartis Pharmaceuticals Corporation | $208.02 | 2024-2025 | |
| Csl Behring | $175.16 | 2021-2025 | Hizentra |
| Teva Pharmaceuticals USA, INC. | $165.27 | 2023-2025 | Austedo Xr, Austedo Xr |
| Azurity Pharmaceuticals, INC. | $154.34 | 2023-2025 | Horizant, Horizant |
| Lundbeck LLC | $151.53 | 2022-2023 | Vyepti |
| Amgen INC. | $139.55 | 2022-2025 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $136.94 | 2021 | |
| Kyowa Kirin, INC. | $136.89 | 2023-2025 | Nourianz |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $131.94 | 2022-2025 | Ultomiris |
| Mdd US Operations, LLC | $122.36 | 2022-2025 | Xadago, Apokyn, Apokyn |
| Aucta Pharmaceuticals, INC. | $117.91 | 2024-2025 | Motpoly Xr |
| Harmony Biosciences LLC | $116.75 | 2021-2025 | Wakix |
| Janssen Pharmaceuticals, INC | $107.44 | 2022 | |
| Alnylam Pharmaceuticals INC. | $104.69 | 2023-2024 | Onpattro |
| Neurelis, INC. | $100.80 | 2023-2025 | Valtoco |
| Otsuka America Pharmaceutical, INC. | $98.92 | 2023-2025 | Rexulti, Nuedexta |
| Merz Pharmaceuticals, LLC | $91.35 | 2025 | Xeomin, Inbrija |
| Astrazeneca Pharmaceuticals LP | $90.00 | 2021-2025 | Wainua |
| Biohaven Pharmaceutical Holding Company LTD. | $87.87 | 2022 | |
| Axsome Therapeutics, INC. | $77.71 | 2023-2025 | Sunosi, Symbravo |
| Ucb, INC. | $76.44 | 2023-2025 | Briviact, Rystiggo |
| Ipsen Biopharmaceuticals, INC | $62.10 | 2024-2025 | Dysport |
| Biogen, INC. | $61.85 | 2022-2024 | Tysabri, Vumerity, Avonex |
| Tg Therapeutics, INC. | $53.54 | 2025 | |
| Jazz Pharmaceuticals INC. | $49.69 | 2023-2025 | |
| Genentech USA, INC. | $49.56 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Grifols USA, LLC | $42.01 | 2022-2025 | Gamunex-C |
| Acorda Therapeutics, INC | $33.03 | 2023-2024 | Inbrija |
| Avion Pharmaceuticals | $30.61 | 2022-2023 | Dhivy |
| Celgene Corporation | $30.00 | 2021 | |
| Emd Serono, INC. | $28.61 | 2023-2024 | Mavenclad |
| Novocure INC. | $28.44 | 2024 | Optune |
| Adamas Pharmaceuticals, INC. | $27.42 | 2021 | |
| Neuronetics, INC. | $26.18 | 2024 | Neurostar Tms Therapy System |
| Avadel Cns Pharmaceuticals, LLC | $20.01 | 2025 | Lumryz |
| Inspire Medical Systems, INC. | $19.87 | 2024 | Inspire |
| Janssen Biotech, INC. | $18.42 | 2025 | |
| Life Molecular Imaging LTD | $16.88 | 2024 | Neuraceq |
| Amneal Pharmaceuticals LLC | $16.62 | 2025 | Brekiya |
| Merck Sharp & Dohme LLC | $16.39 | 2023 | Belsomra |
| Arbor Pharmaceuticals, INC. | $14.99 | 2022 | |
| Banner Life Sciences, LLC | $14.14 | 2023 | |
| Acadia Pharmaceuticals INC | $14.08 | 2025 | Nuplazid |
| Allergan, INC. | $13.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saima Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.